» Articles » PMID: 32857333

Current Evidence on Abuse and Misuse of Gabapentinoids

Overview
Journal Drug Saf
Specialties Pharmacology
Toxicology
Date 2020 Aug 29
PMID 32857333
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

This review summarizes current evidence on the abuse and misuse of the gabapentinoids pregabalin and gabapentin. Pharmacovigilance studies, register-based studies, surveys, clinical toxicology studies, and forensic toxicology studies were identified and scrutinized with the goal to define the problem, identify risk factors, and discuss possible methods to reduce the potential for abuse and misuse. Studies found that gabapentinoids are abused and misused and that individuals with a history of psychiatric disorders or substance use disorder seem to be at high risk. Moreover, some evidence supports the notion that patients with opioid use disorders may be at an increased risk of abusing gabapentinoids. Available evidence also suggests that abuse and misuse are more frequent in users of pregabalin compared with users of gabapentin. Health professionals and prescribers should be aware of the risk for misuse of pregabalin and gabapentin, which eventually could lead to abuse, substance dependence, and intoxications. Prescribing to patients belonging to risk populations such as those with psychiatric disorders or substance use disorder should be avoided if possible and, if prescribed, signs of misuse and abuse should be monitored.

Citing Articles

Analysis of User-Generated Posts on Social Media of Adjuvant Analgesics: A Machine Learning Study.

Carabot F, Donat-Vargas C, Lara-Abelenda F, Martinez O, Santoma J, Garcia-Montero C Int J Med Sci. 2025; 22(1):170-178.

PMID: 39744167 PMC: 11659822. DOI: 10.7150/ijms.96981.


Analgesic use may not decrease in the first postoperative year in patients underwent total knee arthroplasty due to advanced osteoarthritis.

Aslan A, Maytalman E, Gulcu A J Clin Orthop Trauma. 2024; 59:102800.

PMID: 39611163 PMC: 11600055. DOI: 10.1016/j.jcot.2024.102800.


Assessment of community pharmacists' experiences and perceptions on gabapentin abuse in Jordan: a cross-sectional study.

Abu-Farha R, Gharaibeh L, Alzoubi K, Ahmad R, Binsaleh A, Shilbayeh S J Pharm Policy Pract. 2024; 17(1):2430445.

PMID: 39605986 PMC: 11600517. DOI: 10.1080/20523211.2024.2430445.


Examination of optical coherence tomography findings in patients with pregabalin use disorder.

Kilic O, Bayram Z, Kiyat P, Karti O, Aral A, Munis N PeerJ. 2024; 12:e18395.

PMID: 39544426 PMC: 11562773. DOI: 10.7717/peerj.18395.


Gabapentin and pregabalin exposures reported to United States poison centers, 2012-2022.

Carter E, Rine N, Kistamgari S, Hays H, Spiller H, Yang J Inj Epidemiol. 2024; 11(1):59.

PMID: 39487483 PMC: 11529557. DOI: 10.1186/s40621-024-00547-9.


References
1.
Slavova S, Miller A, Bunn T, White J, Kirschke D, Light T . Prevalence of gabapentin in drug overdose postmortem toxicology testing results. Drug Alcohol Depend. 2018; 186:80-85. DOI: 10.1016/j.drugalcdep.2018.01.018. View

2.
Mico J, Prieto R . Elucidating the mechanism of action of pregabalin: α(2)δ as a therapeutic target in anxiety. CNS Drugs. 2012; 26(8):637-48. DOI: 10.2165/11634510-000000000-00000. View

3.
Blanch B, Buckley N, Mellish L, Dawson A, Haber P, Pearson S . Harmonizing post-market surveillance of prescription drug misuse: a systematic review of observational studies using routinely collected data (2000-2013). Drug Saf. 2015; 38(6):553-64. DOI: 10.1007/s40264-015-0294-8. View

4.
Peckham A, Fairman K, Sclar D . Prevalence of Gabapentin Abuse: Comparison with Agents with Known Abuse Potential in a Commercially Insured US Population. Clin Drug Investig. 2017; 37(8):763-773. DOI: 10.1007/s40261-017-0530-3. View

5.
Choi P, Tscharke B, Samanipour S, Hall W, Gartner C, Mueller J . Social, demographic, and economic correlates of food and chemical consumption measured by wastewater-based epidemiology. Proc Natl Acad Sci U S A. 2019; 116(43):21864-21873. PMC: 6815118. DOI: 10.1073/pnas.1910242116. View